Skip to content
lifestyle.cfxmagazine.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Santhera Pharmaceuticals Holding AG
Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea
October 23, 2026
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
September 30, 2026
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
July 13, 2026
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
July 1, 2026
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
June 2, 2026
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
May 26, 2026
Santhera Appoints Stifel as Corporate Finance Advisor
February 12, 2026